Bio-Thera Solutions has started dosing in a Phase I clinical trial of BAT8013, an ADC designed to target CD25, in patients with advanced solid tumours.

The post Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013 appeared first on Clinical Trials Arena.